Cardiotoxicity of the antiproliferative compound fluorouracil

Drugs

Volumn 57, Issue 4, 1999, Pages 475-484

  Becker, Klaus ^a,c   Erckenbrecht, Joachim F ^a   Häussinger, Dieter ^b   Frieling, Thomas ^b  

^a Dept of Int Med/Gastroenterology   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Florence Nightingale Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

CANCER PATIENT; CARDIOTOXICITY; CORONARY ARTERY SPASM; DRUG CYTOTOXICITY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; PROGNOSIS; REVIEW; RISK FACTOR; THORAX PAIN; THORAX RADIOGRAPHY;

ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; GROWTH INHIBITORS; HEART DISEASES; HUMANS;

EID: 0032950467     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957040-00003     Document Type: Review

References (95)

1. 1. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-6
2. 2. Friedman MA, Sadée W. The fluoropyrimidines: biochemical mechanisms and design of clinical trials. Cancer Chemother Pharmacol 1978; 1: 77-82
3. 3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37
4. 4. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993; 71: 493-509
5. 5. Liss RH, Chadwick M. Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 1974; 58: 777-86
6. 6. Andersson M, Domellöf L, Häggmark S, et al. Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). Cancer Chemother Pharmacol 1988; 22: 251-5
7. 7. Gaveau T, Banzet P, Marneffe H, et al. Troubles cardio-vasculaires au cours d'infusions d'anti-mitotiques a fortes doses. 30 observations cliniques. Anesth Anal Réan 1969; 26: 311-27
8. 8. Dent RG, McColl I. 5-Fluorouracil and angina. Lancet 1975; 1: 347-8
9. 9. Roth A, Kolarie K, Popovic S. Cardiotoxicity of 5-fluorouracil (NSC-19893). Cancer Chemother Rep 1975; 59: 1051-2
10. 10. Pottage A, Holt S, Ludgate S, et al. fluorouracil cardiotoxicity. BMJ 1978; 1: 547
11. 11. Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-10
12. 12. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294: 238-43
13. 13. Eskilsson J, Albertsson M, Mercke C. Adverse effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988; 13: 41-6
14. 14. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. Cancer 1988; 62: 266-9
15. 15. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1990; 1: 409-14
16. 16. May D, Wandl U, Becher R, et al. Cardiotoxicity of 5-fluorouracil. Dtsch Med Wschr 1990; 115: 618-21
17. 17. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-801
18. 18. Sorbette F, Simon I, Bonneterre J, et al. Etude prospective multicentrique des accidents cardiaques survenus au cours de traîtements comportant du 5-FU. Thérapie 1992; 47: 371-3
19. 19. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-4
20. 20. Anderson NR, Lokich JJ, Moore C. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993; 72: 2287-8
21. 21. Schöber C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72: 2242-7
22. 22. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374-8
23. 23. McLachlan SA, Millward MJ, Toner GC, et al. The spectrum of 5-fluorouracil cardiotoxicity. Med J Aust 1994; 161: 207-9
24. 24. Weidmann B, Jansen W, Heider A, et al. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 1995; 75: 194-5
25. 25. Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacother 1997; 17: 729-36
26. 26. Escudier B, Alexandre JB, Leclercq B, et al. Cardiotoxicité du 5 fluorouracil: caractéristiques, mécanisme, conduite pratique. Presse Med 1986; 15: 1819-21
27. 27. Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J 1987; 114: 433-6
28. 28. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85: 750-1
29. 29. Leone B, Rabinovich M, Ferrari CR, et al. Cardiotoxicity as a result of 5-fluorouracil therapy. Tumori 1985; 71: 55-7
30. 30. Sanani S, Spaulding MB, Masud ARZ, et al. 5-FU cardiotoxicity. Cancer Treat Rep 1981; 65: 1123-5
31. 31. Chaudary S, Song SYT, Jaski BE. Profound, yet reversible, heart failure secondary to 5-fluorouracil. Am J Med 1988; 85: 454-6
32. 32. McKendall GR, Shurman A, Anamur M, et al. Toxic cardiogenic shock associated with infusion of 5-fluorouracil. Am Heart J 1989; 118: 184-6
33. 33. Luwaert RJ, Descamps O, Majois F, et al. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J 1991; 12: 468-70
34. 34. Unverdorben M, Birkenhake S, Kunkel B, et al. Reversible global left ventricular dysfunction in patent coronary arteries following continuous infusion of 5-fluorouracil (5-FU). Strahlenther Onkol 1994; 170: 461-6
35. 35. Misset B, Escudier B, Leclercq B, et al. Acute myocardiotoxicity during 5-fluorouracil therapy. Intensive Care Med 1990; 16: 210-1
36. 36. Thyss A, Falewee MN, Leborgne L, et al. Cardiotoxicite du 5 fluoro-uracile: spasme ou toxicite myocardique directe? Bull Cancer 1987; 74: 381-5
37. 37. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-33
38. 38. Thyss A, Gaspard MH, Marsault R, et al. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity [letter]. Ann Oncol 1992; 3: 88
39. 39. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries: an electron microscopic study in rabbits. Scanning Microsc 1995; 9: 561-76
40. 40. Cwikiel M, Eskilsson J, Albertsson M, et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium: an experimental study using endothelial cells in the culture. Ann Oncol 1996; 7: 731-7
41. 41. Wenzel DG, Cosma GN. A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts: II. Doxorubicin, 5-fluorouracil and cyclophosphamide. Toxicology 1984; 33: 117-28
42. 42. Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988; 61: 36-45
43. 43. Satoh H, Hashimoto K. Effects of ftorafur and 5-fluorouracil on the canine sinoatrial node. Jpn J Pharmacol 1983; 33: 357-62
44. 44. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oneol 1989; 7: 509-14
45. 45. Millart H, Brabant L, Lorenzato M, et al. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res 1992; 12: 571-6
46. 46. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30: 871-9
47. 47. Arellano M, Malet-Martino M, Martino R, et al. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998; 77: 79-86
48. 31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR). Jpn J Pharmacol 1984; 34: 375-9
49. 49. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970; 23: 155-60
50. 50. Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985; 313: 245-9
51. 51. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5 fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51
52. 52. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 1991; 68: 499-501
53. 53. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 1994; 4: 301-6
54. 54. Petit E, Milano G, Lévi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-9
55. 55. Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201
56. 56. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-53
57. 57. Köhne CH, Thuss-Patience P, Friedrich M, et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77: 973-7
58. 58. Levillain R. Lésions cardiaques observées en microscopic optique chez le rat Wistar après ingestion de 5-fluoro-uracile. J Med Besançon 1972; 8: 37-44
59. 59. Levillain R. Myocardite expérimentale; étude anatomique de 210 coeurs de rats ayant ingéré du 5 fluoro-uracile. C R Soc Biol 1972; 2-3: 340-2
60. 60. Maurer U, Härle M, Jungius KP. 5-Fluorouracil: cause of a fatal myocardial infaretion during combined radiochemotherapy. Strahlenther Onkol 1996; 172: 257-9
61. 61. Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10: 861-4
62. 62. Grandi AM, Pinotti G, Morandi E, et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 1997; 8: 705-8
63. 63. Villani F, Guindani A, Pagnoni A. 5-Fluorouracil cardiotoxicity. Tumori 1979; 65: 487-95
64. 64. Lang Stevenson D, Mikhailidis DP, Gillett DS. Cardiotoxicity of 5-fluorouracil. Lancet 1977; 11: 406-7
65. 65. Kuzel T, Esparaz B, Green D, et al. Thromhogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65: 885-9
66. 66. Lemaire L, Malet-Martino MC, Longo S, et al. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil [letter]. Lancet 1991; 317: 560
67. 67. Lemaire L, Malet-Martino MC, de Forni M, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992; 66: 119-27
68. 68. Praga C, Beretta G, Labianca R. Cardiac toxicity from antitumor therapy. Oncology 1980; 37: 51-8
69. 69. Lieutaud T, Brain E, Golgran-Toledano D, et al. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 1996; 32A: 368-9
70. 70. Clavel M, Siméone P, Grivet B. Toxicité cardiaque du 5-fluorouracile: revue de la littérature, cinq nouveaux cas. Presse Méd 1988; 17: 1675-8
71. 71. Thyss A, Milano G, Schneider M, et al. Circulating drug levels in patients presenting cardiotoxicity to 5-FU. Eur J Cancer Clin Oncol 1988; 24: 1675-6
72. 72. Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 1973; 29: 244-57
73. 73. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-6
74. 74. Escudier B. Conscience G, Nkam M, et al. Cardiotoxicité du 5 fluoro-uracile: a propos d'un nouveau cas. Arch Mal Coeur Vaiss 1985; 10: 1579-81
75. 75. Gradishar W, Vokes E, Schilsky R, et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991; 19: 8-15
76. 76. Vorobiof DA. Cardiotoxicity of 5-fluorouracil. S Afr Med J 1982; 61: 634-5
77. 77. Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49: 282-3
78. 78. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-5
79. 79. Blütters-Sawatzki R, Grathwohl J, Mertens R, et al. Severe cardiotoxicity of high-dose 5-fluorouracil in combination with folinic acid, cisplatin and methotrexate in a 14-year-old boy with nasopharyngeal carcinoma (Schmincke Tumor). Oncol 1995; 52: 291-4
80. 80. Raina A, Ferrante F, Bisol A, et al. Cardiotoxicity during chemotherapy for advanced gastroenteric tumors. Tumori 1987; 73: 359-61
81. 81. Ferrari E, Taillan B, Tibi T, et al. Toxicité cardiaque du fluorouracile: aspects typiques et atypiques. A propos de 8 observations. Ann Cardiol Angéiol 1992; 41: 191-5
82. 82. Soukop M, McVie JG, Calman KC. Flourouracil cardiotoxicity [letter]. BMJ 1978; 1: 1422
83. 83. Coronel B, Madonna O, Mercatello A, et al. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med 1988; 14: 429-30
84. 84. Millward MJ, Ganju V, Buck M. Cardiac arrest: a manifestation of 5-fluorouracil cardiotoxicity. Aust NZ J Med 1988; 18: 693-5
85. 85. Ensley JF, Patel B, Kloner R, et al. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989; 7: 101-9
86. 86. Davidson JA. Prevention of 5 fluorouracil associated cardiotoxicity. Aust NZ J Med 1994; 24: 321
87. 87. Gamucci T, Zampa G. Cardiotoxicity of 5-fluorouracil. Tumori 1980; 66: 635-6
88. 88. Beretta G, Labianca R, Montinari F, et al. Antitumor chemotherapy after fluorouracil angina. J Cancer Res Clin Oncol 1982; 104: 321-2
89. 89. Baker WP, Dainer P, Lester WM, et al. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986; 57: 497-8
90. 90. Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993; 29A: 740-4
91. 91. Farooqi IS, Aronson JK. latrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. Q J Med 1996; 89: 953-5
92. 92. Kleiman NS, Lehane DE, Geyer CE, et al. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med 1987; 82: 566-8
93. 93. Orditura M, de Vita F, Sarubbi B, et al. Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients. Oncol Rep 1998; 5: 645-7
94. 94. Braunwald E, Kloner RA. The stunned myocardium syndrome: prolonged postischemic ventricular dysfunction. Circulation 1982; 66: 429-38
95. 95. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-82